Integra Lifesciences Holdings (IART) Depreciation & Amortization (CF) (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $38.4 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 3.34% year-over-year to $38.4 million; the trailing twelve-month figure through Mar 2026 stood at $153.1 million (up 3.77% YoY), and the FY2025 full-year result was $151.8 million, up 7.76% from the prior year.
• Depreciation & Amortization (CF) held at $38.4 million in Q1 2026, from $38.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $38.5 million in Q3 2025 to a low of $29.5 million in Q3 2022.
• A 5-year average of $33.7 million and a median of $31.1 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) dropped 4.07% in 2022 and rose 21.66% in 2025, its largest moves.
• Tracing IART's Depreciation & Amortization (CF) over 5 years: stood at $29.5 million in 2022, then advanced by 5.05% to $31.0 million in 2023, then climbed by 21.31% to $37.6 million in 2024, then grew by 2.24% to $38.4 million in 2025, then changed by 0.0% to $38.4 million in 2026.
• Business Quant data shows IART's Depreciation & Amortization (CF) at $38.4 million in Q1 2026, $38.4 million in Q4 2025, and $38.5 million in Q3 2025.